Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Role of QRX-3 a Novel NAD Modulator in Ambulatory Chronic Kidney Patients

NCT06948292 is registered in ClinicalTrials.gov with Ebima Clifford Okundaye as lead sponsor.

NCT NCT06948292
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06948292 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Role of QRX-3 a Novel NAD Modulator in Ambulatory Chronic Kidney Patients
Lead sponsor
Ebima Clifford Okundaye
Phase
Phase 2
Overall status
Completed
Start date
March 1, 2023
Completion date
October 30, 2024
Enrollment
127 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease stages 3-5, diabetic kidney disease, hypertensive kidney disease